Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

May 18, 2020

Conditions
Primary Sclerosing Cholangitis
Interventions
DRUG

Cilofexor

Tablet(s) administered orally once daily with food

DRUG

Placebo to match cilofexor

Tablet(s) administered orally once daily with food

Trial Locations (23)

22908

University of Virginia, Charlottesville

23226

Bon Secours St. Mary's Hospital of Richmond, Inc., Richmond

23249

McGuire VA Medical Center, Richmond

23298

Virginia Commonwealth University, Richmond

27710

Duke University Medical Center, Durham

33136

Schiff Center for Liver Diseases/University of Miami, Miami

34211

Florida Digestive Health Specialists, Lakewood Rch

46202

Indiana University Health University Hospital, Indianapolis

55117

Minnesota Gastroenterology, P.A., Saint Paul

75203

The Liver Institute at Methodist Dallas Medical Center, Dallas

80045

University of Colorado Denver, Aurora

84107

Intermountain Medical Center - Transplant Services, Murray

94143

University of California San Francisco, San Francisco

95817

University of California, Davis Medical Center, Sacramento

98104

Swedish Organ Transplant and Liver Center, Seattle

University of Washington, Seattle

Unknown

Universitätsklinik Klinik für Innere Medizin III, Vienna

University of Calgary Liver Unit (Heritage Medical Research Clinic), Calgary

New Queen Elizabeth Hospital NHS Foundation Trust, Birmingham

M6H 3M1

Toronto Liver Centre, Toronto

NW3 2QG

Royal Free Hospital, London

SE5 9RS

King's College Hospital NHS Foundation Trust, London

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY